Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

365 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial.
Galanis E, Dooley KE, Keith Anderson S, Kurokawa CB, Carrero XW, Uhm JH, Federspiel MJ, Leontovich AA, Aderca I, Viker KB, Hammack JE, Marks RS, Robinson SI, Johnson DR, Kaufmann TJ, Buckner JC, Lachance DH, Burns TC, Giannini C, Raghunathan A, Iankov ID, Parney IF. Galanis E, et al. Nat Commun. 2024 Jan 12;15(1):493. doi: 10.1038/s41467-023-43076-7. Nat Commun. 2024. PMID: 38216554 Free PMC article. Clinical Trial.
Phase II trial of gemcitabine in advanced sarcomas.
Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E. Okuno S, et al. Among authors: galanis e. Cancer. 2002 Jun 15;94(12):3225-9. doi: 10.1002/cncr.10602. Cancer. 2002. PMID: 12115355 Free article. Clinical Trial.
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ; North Central Cancer Treatment Group. Galanis E, et al. J Clin Oncol. 2005 Aug 10;23(23):5294-304. doi: 10.1200/JCO.2005.23.622. Epub 2005 Jul 5. J Clin Oncol. 2005. PMID: 15998902 Clinical Trial.
Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R, Giannini C, Krempski J, Peng KW, Goble JM, Uhm JH, Russell SJ, Galanis E. Allen C, et al. Among authors: galanis e. Cancer Res. 2006 Dec 15;66(24):11840-50. doi: 10.1158/0008-5472.CAN-06-1200. Cancer Res. 2006. PMID: 17178881
365 results